Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Conditions
Brief summary
The purpose of this study is to test the safety of vorinostat (Zolinza) and azacitidine (Vidaza) when combined with gemtuzumab ozogamicin (GO) at different dose levels. These drugs increase the effect of GO against leukemia cells in the test tube, but we don't know yet whether they also increase the anti-leukemia effect of GO in people.
Detailed description
PRIMARY OBJECTIVES: I. Determine the vorinostat dose with the most favorable efficacy and toxicity when combined with azacitidine and GO. SECONDARY OBJECTIVES: I. Describe the complete response (CR)/ CR with inadequate recovery (CRi) rate after a total of 6 cycles of therapy. II. Describe the disease-free survival of patients that achieve CR/CRi. III. Determine whether acute myeloid leukemia (AML) characteristics associated with preclinical GO efficacy predict for clinical benefit, and assess whether differentiation-inducing agents modulate these characteristics and lower the apoptotic threshold for calicheamicin-gamma1-induced cytotoxicity (in vitro correlative and mechanistic studies). OUTLINE: This is phase I, dose-escalation study of vorinostat followed by a phase II study. Patients receive vorinostat orally (PO) on days 1-9, azacitidine subcutaneously (SC) or intravenously (IV) over 10-40 minutes on days 1-7, and gemtuzumab ozogamicin IV over 2 hours on day 4 and 8. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 3 years.
Interventions
DRUGvorinostat
Given orally
DRUGgemtuzumab ozogamicin
Given intravenously (IV)
DRUGazacitidine
Given IV or subcutaneously (SC)
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Prior morphological diagnosis of acute myeloid leukemia (AML) other then acute promyelocytic leukemia (APL) according to the 2001 WHO criteria; patients with biphenotypic AML are eligible * Need for first salvage chemotherapy for persistent or relapsing disease, defined by standard criteria, after at least one course of conventional chemotherapy * A bone marrow biopsy is not required but should be obtained if the aspirate is dilute, hypocellular, or not aspirable; outside marrow exams performed within the stipulated time period are acceptable if the slides are reviewed at the study institution * Flow cytometric analysis of the marrow aspirate per institutional practice guidelines * Duration of first complete remission (CR1) \< 12 months (or primary resistant disease) * Patients with prior autologous or allogeneic hematopoietic cell transplantation (HCT) if relapse occurs 6-12 months post-transplant * ECOG/WHO/Zubrod performance status of 0-3 within 14 days prior to registration * Off any active therapy for AML except hydroxyurea for at least 14 days prior to study registration, with resolution of all grade 3 and 4 non-hematological toxicities * Willingness to discontinue taking any medications known to cause a risk of Torsades de Pointes * Bilirubin =\< 1.5 x Institutional Upper Limit of Normal (IULN) unless elevation is due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis (within 7 days prior to registration) * SGOT (AST) and SGPT (ALT) =\< 1.5 x IULN unless elevation is due to hepatic infiltration by AML (within 7 days prior to registration) * Serum creatinine =\< 1.5 x IULN (within 7 days prior to registration) * No clinical or radiographical evidence of heart failure * white blood cell (WBC) \< 25,000/uL within 3 days prior to registration * Patients with symptoms/signs of hyperleukocytosis or WBC \> 100,000/uL can be treated with leukapheresis prior to enrollment * Collection of bone marrow and peripheral blood specimens for correlative studies prior to study treatment is highly recommended; peripheral blood only is acceptable if the peripheral blast count is \> 5,000/uL and \> 50% of total WBC * Must agree to use adequate contraception prior to and during the study * Can understand and sign a written informed consent document; a legally authorized representative can provide consent if the patient is unable
Exclusion criteria
* Remission or second or later relapse * Diagnosis of another malignancy, unless diagnosed at least 2 years earlier and disease-free for at least 6 months after completion of curative intent therapy except: * Treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, if definitive treatment has been completed * Organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values if hormonal therapy has been initiated or a radical prostatectomy was performed * Refractory/relapsing blast crisis of chronic myeloid leukemia (CML) * Prior anti-AML treatment with GO, histone deacetylase (HDAC) inhibitor (including the use of valproic acid for control of seizure activity or other purposes), or demethylating agent * Known hypersensitivity to GO, vorinostat, azacitidine, or mannitol * Possible central nervous system (CNS) involvement with leukemia unless a lumbar puncture confirms no leukemic blasts in the cerebralspinal fluid (CSF) * HIV-positive patients with cluster of differentiation (CD)4 count is \< 200 cells/uL or if AIDS-related complications * Pregnancy; breastfeeding should be discontinued if the mother is treated with vorinostat, azacitidine, and GO * Uncontrolled systemic infection, despite appropriate antibiotics or other treatment) * Receipt of any other investigational agents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants With Dose-limiting Toxicity (Phase I) | 42 days |
| Number of Participants With Dose-limiting Toxicity After the Vorinostat Dose | Up to 3 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Complete Remission | up to 3 years | Efficacy Defined as Best Response Achieved During Study Treatment Measured by Complete Remission (CR) Rate |
| Disease Relapse | up to 2 years | — |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Phase 1 Dose-Finding Cohorts 1-3 Patients receive vorinostat PO on days 1-9, azacitidine SC or IV over 10-40 minutes on days 1-7, and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
vorinostat: Given orally
gemtuzumab ozogamicin: Given IV
azacitidine: Given IV or SC
laboratory biomarker analysis: Correlative studies | 9 |
| Phase 2/Selected Dose Azacitidine 75 mg/m2 SC or IV on days 1-7, vorinostat 400 mg qd po on days 1-9, gemtuzumab ozogamicin 3 mg/m2 IV on days 4 and 8. Includes cohort 4 from the Phase 1 portion of the study. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. | 43 |
| Total | 52 |
Baseline characteristics
| Characteristic | Phase 1 Dose-Finding Cohorts 1-3 | Phase 2/Selected Dose | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 5 Participants | 22 Participants | 27 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants | 21 Participants | 25 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 1 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants | 40 Participants | 46 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 6 Participants | 6 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) White | 8 Participants | 34 Participants | 42 Participants |
| Region of Enrollment United States | 9 Participants | 43 Participants | 52 Participants |
| Sex: Female, Male Female | 5 Participants | 18 Participants | 23 Participants |
| Sex: Female, Male Male | 4 Participants | 25 Participants | 29 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 9 / 15 | 43 / 43 |
| serious Total, serious adverse events | 6 / 15 | 13 / 43 |
Outcome results
Primary
Number of Participants With Dose-limiting Toxicity After the Vorinostat Dose
Time frame: Up to 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose 1 | Number of Participants With Dose-limiting Toxicity After the Vorinostat Dose | 4 participants |
| Dose 2 | Number of Participants With Dose-limiting Toxicity After the Vorinostat Dose | 18 participants |
Primary
Number of Participants With Dose-limiting Toxicity (Phase I)
Time frame: 42 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose 1 | Number of Participants With Dose-limiting Toxicity (Phase I) | 0 participants |
| Dose 2 | Number of Participants With Dose-limiting Toxicity (Phase I) | 0 participants |
| Dose 3 | Number of Participants With Dose-limiting Toxicity (Phase I) | 0 participants |
| Dose 4 | Number of Participants With Dose-limiting Toxicity (Phase I) | 1 participants |
Secondary
Disease Relapse
Time frame: up to 2 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dose 1 | Disease Relapse | 5 Participants |
Secondary
Number of Participants With Complete Remission
Efficacy Defined as Best Response Achieved During Study Treatment Measured by Complete Remission (CR) Rate
Time frame: up to 3 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dose 1 | Number of Participants With Complete Remission | 18 Participants |